Abstract

Most of the Parkinson’s disease (PD) cases are sporadic, although several genes are directly related to PD. Several pathways are central in PD pathogenesis: protein aggregation linked to proteasomal impairments, mitochondrial dysfunctions and impairment in dopamine (DA) release. Here we studied the close crossing of mitochondrial dysfunction and aggregation of α-synuclein (α-syn) and in the extension in the dopaminergic neuronal death. Here, using rat primary cultures of mesencephalic neurons, we induced the mitochondrial impairments using “DA-toxins” (MPP+, 6OHDA, rotenone). We showed that the DA-Toxins induced dopaminergic cell death through different pathways: caspase-dependent cell death for 6OHDA; MPP+ stimulated caspase-independent cell death, and rotenone activated both pathways. In addition, a decrease in energy production and/or a development of oxidative stress were observed and were linked to α-syn aggregation with generation of Lewy body-like inclusions (found inside and outside the dopaminergic neurons). We demonstrated that any of induced mitochondrial disturbances and processes of death led to α-syn protein aggregation and finally to cell death. Our study depicts the cell death mechanisms taking place in in vitro models of Parkinson’s disease and how mitochondrial dysfunctions is at the cross road of the pathologies of this disease.

Highlights

  • Parkinson’s disease (PD) is a common neurodegenerative movement disorder that affects around 1% of the population over the age of 70[1]

  • We showed that DA-toxins induced a decrease in energy production, oxidative stress linked to α-syn aggregation and generation of Lewy body (LB)-like inclusions, and dopaminergic neuronal death through different cell death pathways

  • We showed that whatever the mechanisms of cell death observed, α-synuclein (α-syn) production and aggregation always occurred

Read more

Summary

Introduction

Parkinson’s disease (PD) is a common neurodegenerative movement disorder that affects around 1% of the population over the age of 70[1]. It is the second most common neurodegenerative disease after Alzheimer’s disease. The patients suffering from PD display symptoms of motor instabilities with resting tremor as the first symptom in 70% of the cases. Other clinical symptoms are rigidity, bradykinesia and postural instability, and often include cognitive impairment, depression and sleep disorders[2]. Environmental risk factors and their interaction play a major role in PD.

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call